Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 106 | 2022 | 4946 | 6.280 |
Why?
|
Medication Adherence | 15 | 2022 | 137 | 4.190 |
Why?
|
Male | 128 | 2022 | 6489 | 3.260 |
Why?
|
Middle Aged | 85 | 2022 | 3425 | 2.920 |
Why?
|
Humans | 161 | 2022 | 14077 | 2.880 |
Why?
|
Neurocognitive Disorders | 11 | 2021 | 13 | 2.880 |
Why?
|
Anti-Retroviral Agents | 16 | 2021 | 542 | 2.850 |
Why?
|
AIDS Dementia Complex | 14 | 2021 | 29 | 2.790 |
Why?
|
Female | 122 | 2021 | 8751 | 2.600 |
Why?
|
Adult | 100 | 2021 | 5664 | 2.510 |
Why?
|
Antiretroviral Therapy, Highly Active | 29 | 2021 | 468 | 2.490 |
Why?
|
Aged | 46 | 2022 | 1650 | 2.360 |
Why?
|
Anti-HIV Agents | 30 | 2021 | 1275 | 2.340 |
Why?
|
Cognition Disorders | 14 | 2018 | 35 | 2.220 |
Why?
|
Text Messaging | 5 | 2020 | 25 | 2.140 |
Why?
|
Frailty | 6 | 2021 | 15 | 2.080 |
Why?
|
Cognitive Dysfunction | 4 | 2021 | 12 | 1.840 |
Why?
|
Brain | 10 | 2021 | 53 | 1.830 |
Why?
|
Neuropsychological Tests | 28 | 2022 | 55 | 1.810 |
Why?
|
Bipolar Disorder | 5 | 2019 | 5 | 1.790 |
Why?
|
Alzheimer Disease | 5 | 2021 | 30 | 1.720 |
Why?
|
Aging | 12 | 2021 | 109 | 1.720 |
Why?
|
Depression | 6 | 2022 | 117 | 1.720 |
Why?
|
Hospitalization | 13 | 2021 | 392 | 1.690 |
Why?
|
Pneumonia | 3 | 2021 | 127 | 1.550 |
Why?
|
Inflammation | 3 | 2021 | 103 | 1.480 |
Why?
|
HIV-1 | 12 | 2021 | 1239 | 1.360 |
Why?
|
Mycobacterium tuberculosis | 6 | 2022 | 326 | 1.310 |
Why?
|
Risk Factors | 33 | 2021 | 1431 | 1.250 |
Why?
|
Infant | 34 | 2021 | 2145 | 1.190 |
Why?
|
Reminder Systems | 2 | 2019 | 8 | 1.150 |
Why?
|
Pneumococcal Vaccines | 10 | 2019 | 252 | 1.150 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2021 | 194 | 1.150 |
Why?
|
Cross-Sectional Studies | 22 | 2022 | 1377 | 1.120 |
Why?
|
Child, Preschool | 28 | 2021 | 1675 | 1.110 |
Why?
|
Pre-Exposure Prophylaxis | 5 | 2022 | 171 | 1.100 |
Why?
|
Tuberculosis, Multidrug-Resistant | 5 | 2022 | 210 | 1.100 |
Why?
|
Executive Function | 6 | 2020 | 23 | 1.060 |
Why?
|
Methamphetamine | 7 | 2020 | 7 | 1.060 |
Why?
|
Pneumococcal Infections | 8 | 2019 | 287 | 1.040 |
Why?
|
Age Factors | 6 | 2020 | 364 | 1.030 |
Why?
|
Telemedicine | 3 | 2020 | 25 | 0.990 |
Why?
|
Quality of Life | 6 | 2021 | 170 | 0.930 |
Why?
|
HIV Seropositivity | 8 | 2020 | 263 | 0.910 |
Why?
|
Neurodegenerative Diseases | 3 | 2018 | 19 | 0.910 |
Why?
|
Cohort Studies | 24 | 2021 | 939 | 0.900 |
Why?
|
Logistic Models | 16 | 2021 | 252 | 0.890 |
Why?
|
Coinfection | 7 | 2021 | 268 | 0.890 |
Why?
|
Comorbidity | 13 | 2021 | 184 | 0.890 |
Why?
|
Viral Load | 15 | 2020 | 808 | 0.880 |
Why?
|
Adolescent | 36 | 2021 | 2858 | 0.850 |
Why?
|
Aged, 80 and over | 10 | 2022 | 449 | 0.850 |
Why?
|
Amphetamine-Related Disorders | 4 | 2020 | 5 | 0.830 |
Why?
|
HIV Seronegativity | 3 | 2020 | 52 | 0.820 |
Why?
|
Case-Control Studies | 16 | 2022 | 464 | 0.800 |
Why?
|
Longitudinal Studies | 9 | 2021 | 409 | 0.750 |
Why?
|
Streptococcus pneumoniae | 6 | 2017 | 320 | 0.730 |
Why?
|
CD4 Lymphocyte Count | 21 | 2021 | 654 | 0.720 |
Why?
|
Health Services Accessibility | 3 | 2019 | 265 | 0.690 |
Why?
|
Prevalence | 16 | 2020 | 1149 | 0.690 |
Why?
|
Disease Management | 2 | 2019 | 73 | 0.690 |
Why?
|
Primary Health Care | 5 | 2018 | 228 | 0.680 |
Why?
|
Substance-Related Disorders | 8 | 2019 | 49 | 0.670 |
Why?
|
Population Groups | 1 | 2019 | 9 | 0.670 |
Why?
|
Young Adult | 23 | 2021 | 2357 | 0.670 |
Why?
|
Sexual Behavior | 6 | 2019 | 313 | 0.670 |
Why?
|
Psychotherapy | 1 | 2019 | 2 | 0.670 |
Why?
|
Needs Assessment | 1 | 2019 | 29 | 0.660 |
Why?
|
Organophosphates | 2 | 2019 | 8 | 0.660 |
Why?
|
Central Nervous System Stimulants | 3 | 2016 | 4 | 0.660 |
Why?
|
Child | 22 | 2021 | 2180 | 0.660 |
Why?
|
Patient Education as Topic | 1 | 2019 | 48 | 0.650 |
Why?
|
Follow-Up Studies | 16 | 2021 | 367 | 0.650 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 23 | 0.640 |
Why?
|
Rural Health Services | 1 | 2019 | 48 | 0.640 |
Why?
|
Adenine | 2 | 2019 | 88 | 0.630 |
Why?
|
Hypertension | 3 | 2019 | 397 | 0.620 |
Why?
|
Homosexuality, Male | 7 | 2022 | 48 | 0.600 |
Why?
|
Alcoholism | 1 | 2017 | 17 | 0.580 |
Why?
|
Cystatin C | 1 | 2017 | 9 | 0.570 |
Why?
|
South Africa | 26 | 2021 | 7312 | 0.560 |
Why?
|
Tuberculosis, Pulmonary | 4 | 2017 | 320 | 0.560 |
Why?
|
Developing Countries | 6 | 2021 | 385 | 0.550 |
Why?
|
Treatment Outcome | 12 | 2021 | 867 | 0.540 |
Why?
|
Picornaviridae Infections | 3 | 2021 | 18 | 0.530 |
Why?
|
Immunoconjugates | 1 | 2015 | 1 | 0.530 |
Why?
|
Antipsychotic Agents | 2 | 2012 | 10 | 0.530 |
Why?
|
Retrospective Studies | 16 | 2021 | 767 | 0.520 |
Why?
|
HIV | 4 | 2018 | 380 | 0.520 |
Why?
|
Pharmaceutical Preparations | 1 | 2015 | 44 | 0.510 |
Why?
|
Mental Recall | 1 | 2015 | 3 | 0.510 |
Why?
|
Pain | 1 | 2015 | 40 | 0.500 |
Why?
|
Antitubercular Agents | 6 | 2022 | 299 | 0.500 |
Why?
|
Tuberculosis | 5 | 2014 | 530 | 0.500 |
Why?
|
Craniosynostoses | 1 | 2015 | 1 | 0.490 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 5 | 0.490 |
Why?
|
Blood Transfusion | 1 | 2015 | 11 | 0.490 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 137 | 0.480 |
Why?
|
Vaccination | 5 | 2021 | 347 | 0.480 |
Why?
|
Pneumonia, Viral | 3 | 2021 | 102 | 0.470 |
Why?
|
Child Development | 1 | 2015 | 89 | 0.460 |
Why?
|
Infant, Newborn | 11 | 2021 | 1410 | 0.450 |
Why?
|
Activities of Daily Living | 7 | 2017 | 39 | 0.450 |
Why?
|
Incidence | 14 | 2021 | 655 | 0.430 |
Why?
|
Nasopharynx | 4 | 2021 | 148 | 0.430 |
Why?
|
Respiratory System | 1 | 2012 | 9 | 0.420 |
Why?
|
Health Status Indicators | 2 | 2020 | 17 | 0.410 |
Why?
|
Child Health | 3 | 2021 | 76 | 0.410 |
Why?
|
Cognition | 5 | 2022 | 75 | 0.400 |
Why?
|
Rhinovirus | 3 | 2021 | 23 | 0.400 |
Why?
|
Pancreatitis, Chronic | 2 | 2021 | 4 | 0.400 |
Why?
|
Virus Diseases | 1 | 2012 | 55 | 0.400 |
Why?
|
Patient Acuity | 2 | 2021 | 18 | 0.390 |
Why?
|
Exercise | 4 | 2019 | 203 | 0.380 |
Why?
|
Bayes Theorem | 2 | 2021 | 77 | 0.380 |
Why?
|
Amyloid beta-Peptides | 4 | 2019 | 22 | 0.370 |
Why?
|
Transgender Persons | 3 | 2019 | 21 | 0.370 |
Why?
|
California | 6 | 2017 | 9 | 0.360 |
Why?
|
Surveys and Questionnaires | 9 | 2021 | 532 | 0.360 |
Why?
|
Mental Status and Dementia Tests | 2 | 2021 | 5 | 0.350 |
Why?
|
Depressive Disorder | 2 | 2020 | 10 | 0.340 |
Why?
|
Feasibility Studies | 4 | 2019 | 95 | 0.340 |
Why?
|
Community-Acquired Infections | 1 | 2010 | 93 | 0.340 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2010 | 93 | 0.340 |
Why?
|
Genotype | 5 | 2019 | 430 | 0.340 |
Why?
|
Risk-Taking | 4 | 2019 | 119 | 0.330 |
Why?
|
Prospective Studies | 13 | 2021 | 1131 | 0.330 |
Why?
|
Uveitis | 2 | 2019 | 5 | 0.330 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2020 | 25 | 0.330 |
Why?
|
Gastroesophageal Reflux | 2 | 2021 | 3 | 0.330 |
Why?
|
Metabolic Syndrome | 2 | 2020 | 63 | 0.330 |
Why?
|
Secondary Prevention | 2 | 2022 | 20 | 0.320 |
Why?
|
Focus Groups | 3 | 2020 | 180 | 0.320 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 112 | 0.310 |
Why?
|
Proteins | 2 | 2019 | 20 | 0.310 |
Why?
|
Uganda | 12 | 2016 | 194 | 0.310 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2014 | 186 | 0.310 |
Why?
|
Sexual and Gender Minorities | 2 | 2019 | 28 | 0.310 |
Why?
|
Primary Prevention | 2 | 2019 | 27 | 0.300 |
Why?
|
Infant Mortality | 2 | 2010 | 92 | 0.300 |
Why?
|
Unsafe Sex | 2 | 2019 | 45 | 0.290 |
Why?
|
Vaccines, Conjugate | 3 | 2019 | 161 | 0.290 |
Why?
|
Biomarkers | 5 | 2022 | 322 | 0.280 |
Why?
|
Sustained Virologic Response | 2 | 2017 | 22 | 0.280 |
Why?
|
Mass Screening | 4 | 2018 | 242 | 0.280 |
Why?
|
RNA, Viral | 6 | 2020 | 303 | 0.270 |
Why?
|
Mobile Applications | 2 | 2016 | 12 | 0.260 |
Why?
|
Sexual Partners | 5 | 2019 | 211 | 0.260 |
Why?
|
Cardiovascular Agents | 2 | 2016 | 11 | 0.260 |
Why?
|
Pneumonia, Bacterial | 2 | 2016 | 54 | 0.260 |
Why?
|
Coronary Disease | 2 | 2016 | 17 | 0.260 |
Why?
|
Social Support | 2 | 2018 | 76 | 0.260 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 235 | 0.260 |
Why?
|
Veterans | 2 | 2016 | 2 | 0.250 |
Why?
|
Multivariate Analysis | 6 | 2019 | 171 | 0.250 |
Why?
|
Memory | 3 | 2021 | 3 | 0.240 |
Why?
|
Graft Survival | 2 | 2021 | 40 | 0.240 |
Why?
|
Cause of Death | 2 | 2017 | 206 | 0.240 |
Why?
|
Socioeconomic Factors | 7 | 2015 | 405 | 0.240 |
Why?
|
Alcohol Drinking | 2 | 2017 | 53 | 0.230 |
Why?
|
Depressive Disorder, Major | 2 | 2022 | 20 | 0.220 |
Why?
|
African Americans | 2 | 2020 | 47 | 0.220 |
Why?
|
Predictive Value of Tests | 4 | 2018 | 183 | 0.220 |
Why?
|
Visual Acuity | 2 | 2021 | 4 | 0.210 |
Why?
|
Severity of Illness Index | 5 | 2019 | 243 | 0.210 |
Why?
|
Diagnosis, Differential | 2 | 2021 | 63 | 0.210 |
Why?
|
Neopterin | 1 | 2022 | 4 | 0.200 |
Why?
|
Risk Assessment | 4 | 2016 | 217 | 0.200 |
Why?
|
Syphilis | 1 | 2022 | 14 | 0.200 |
Why?
|
Recurrence | 1 | 2022 | 27 | 0.200 |
Why?
|
Cerebral Amyloid Angiopathy | 2 | 2019 | 2 | 0.200 |
Why?
|
Frail Elderly | 1 | 2021 | 15 | 0.200 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 3 | 2012 | 19 | 0.200 |
Why?
|
Serogroup | 3 | 2017 | 134 | 0.200 |
Why?
|
Trypsin | 1 | 2021 | 2 | 0.200 |
Why?
|
Pancreatectomy | 1 | 2021 | 2 | 0.200 |
Why?
|
Graft Rejection | 1 | 2021 | 14 | 0.200 |
Why?
|
Tenofovir | 2 | 2021 | 158 | 0.200 |
Why?
|
Anxiety Disorders | 1 | 2021 | 13 | 0.190 |
Why?
|
Qualitative Research | 2 | 2020 | 294 | 0.190 |
Why?
|
Kidney Transplantation | 1 | 2021 | 42 | 0.190 |
Why?
|
Coronavirus | 1 | 2021 | 14 | 0.190 |
Why?
|
Cerebral Cortex | 2 | 2015 | 9 | 0.190 |
Why?
|
Uveitis, Posterior | 1 | 2021 | 1 | 0.190 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2018 | 37 | 0.190 |
Why?
|
Endpoint Determination | 1 | 2021 | 8 | 0.190 |
Why?
|
Air Pollution | 1 | 2021 | 2 | 0.190 |
Why?
|
Anxiety | 1 | 2021 | 39 | 0.190 |
Why?
|
Animals | 2 | 2015 | 1063 | 0.190 |
Why?
|
Biomedical Technology | 1 | 2021 | 10 | 0.190 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 101 | 0.190 |
Why?
|
Life Expectancy | 2 | 2019 | 31 | 0.190 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2018 | 33 | 0.190 |
Why?
|
Air Pollution, Indoor | 1 | 2021 | 13 | 0.180 |
Why?
|
Genome, Bacterial | 2 | 2018 | 28 | 0.180 |
Why?
|
Reoperation | 1 | 2020 | 8 | 0.180 |
Why?
|
Diagnostic Self Evaluation | 1 | 2020 | 3 | 0.180 |
Why?
|
Hand Strength | 1 | 2020 | 7 | 0.180 |
Why?
|
Impulsive Behavior | 1 | 2020 | 2 | 0.180 |
Why?
|
Apathy | 1 | 2020 | 2 | 0.180 |
Why?
|
Healthy Aging | 1 | 2020 | 6 | 0.180 |
Why?
|
Motor Skills | 1 | 2020 | 6 | 0.180 |
Why?
|
Minority Groups | 1 | 2020 | 4 | 0.180 |
Why?
|
Sentinel Surveillance | 2 | 2019 | 110 | 0.180 |
Why?
|
C-Reactive Protein | 1 | 2021 | 96 | 0.180 |
Why?
|
Age Distribution | 1 | 2020 | 106 | 0.180 |
Why?
|
Diabetes Mellitus | 2 | 2021 | 137 | 0.180 |
Why?
|
Genetic Variation | 3 | 2019 | 169 | 0.180 |
Why?
|
Coronavirus Infections | 1 | 2021 | 70 | 0.170 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 4 | 0.170 |
Why?
|
Cell Phone | 1 | 2020 | 34 | 0.170 |
Why?
|
Uveitis, Anterior | 1 | 2019 | 1 | 0.170 |
Why?
|
Mutation | 5 | 2021 | 299 | 0.170 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 158 | 0.170 |
Why?
|
Plaque, Amyloid | 1 | 2019 | 1 | 0.170 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 3 | 0.170 |
Why?
|
Rural Health | 3 | 2016 | 118 | 0.170 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 19 | 0.170 |
Why?
|
Aqueous Humor | 1 | 2019 | 5 | 0.170 |
Why?
|
Liver Transplantation | 1 | 2020 | 53 | 0.170 |
Why?
|
Photometry | 1 | 2019 | 1 | 0.170 |
Why?
|
Tomography, Optical Coherence | 1 | 2019 | 3 | 0.170 |
Why?
|
Anterior Chamber | 1 | 2019 | 4 | 0.170 |
Why?
|
Congresses as Topic | 1 | 2019 | 20 | 0.170 |
Why?
|
Viremia | 1 | 2020 | 66 | 0.170 |
Why?
|
Islands | 1 | 2019 | 2 | 0.170 |
Why?
|
Lakes | 1 | 2019 | 3 | 0.170 |
Why?
|
Peru | 1 | 2019 | 8 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 132 | 0.170 |
Why?
|
Menopause | 1 | 2019 | 24 | 0.170 |
Why?
|
Rubella Syndrome, Congenital | 1 | 2019 | 5 | 0.170 |
Why?
|
World Health Organization | 1 | 2020 | 134 | 0.170 |
Why?
|
Altitude | 1 | 2019 | 9 | 0.170 |
Why?
|
Caregivers | 2 | 2021 | 66 | 0.170 |
Why?
|
Macular Edema | 1 | 2019 | 1 | 0.170 |
Why?
|
Life Style | 2 | 2018 | 80 | 0.160 |
Why?
|
Cerebrospinal Fluid | 2 | 2017 | 5 | 0.160 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 17 | 0.160 |
Why?
|
Neurofibrillary Tangles | 1 | 2019 | 1 | 0.160 |
Why?
|
tau Proteins | 1 | 2019 | 7 | 0.160 |
Why?
|
Atrophy | 1 | 2019 | 6 | 0.160 |
Why?
|
Guidelines as Topic | 1 | 2019 | 40 | 0.160 |
Why?
|
Glucocorticoids | 1 | 2019 | 20 | 0.160 |
Why?
|
Neurons | 1 | 2019 | 23 | 0.160 |
Why?
|
Research | 1 | 2019 | 65 | 0.160 |
Why?
|
Psychology | 1 | 2018 | 4 | 0.160 |
Why?
|
Inflammation Mediators | 1 | 2019 | 22 | 0.160 |
Why?
|
Endemic Diseases | 1 | 2018 | 15 | 0.160 |
Why?
|
Bacterial Infections | 1 | 2019 | 53 | 0.160 |
Why?
|
Autopsy | 2 | 2019 | 131 | 0.160 |
Why?
|
Carrier State | 1 | 2019 | 89 | 0.160 |
Why?
|
Population Surveillance | 2 | 2021 | 325 | 0.160 |
Why?
|
Europe | 5 | 2017 | 53 | 0.160 |
Why?
|
Polymerase Chain Reaction | 2 | 2016 | 260 | 0.160 |
Why?
|
Personal Satisfaction | 1 | 2018 | 16 | 0.160 |
Why?
|
Apolipoprotein E4 | 2 | 2021 | 4 | 0.150 |
Why?
|
Bacteremia | 2 | 2017 | 79 | 0.150 |
Why?
|
Time Factors | 6 | 2018 | 503 | 0.150 |
Why?
|
Quality of Health Care | 1 | 2018 | 58 | 0.150 |
Why?
|
Health Services Research | 1 | 2018 | 57 | 0.150 |
Why?
|
Ambulatory Care | 1 | 2018 | 54 | 0.150 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 20 | 0.150 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 2 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 168 | 0.140 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 6 | 0.140 |
Why?
|
Blood Coagulation Disorders | 1 | 2017 | 6 | 0.140 |
Why?
|
Immunocompromised Host | 1 | 2017 | 33 | 0.140 |
Why?
|
Chagas Disease | 1 | 2017 | 1 | 0.140 |
Why?
|
Health Risk Behaviors | 1 | 2017 | 7 | 0.140 |
Why?
|
Antigens, CD | 1 | 2017 | 23 | 0.140 |
Why?
|
Emigrants and Immigrants | 1 | 2017 | 11 | 0.140 |
Why?
|
Vascular Remodeling | 1 | 2017 | 1 | 0.140 |
Why?
|
Antibodies, Viral | 1 | 2019 | 266 | 0.140 |
Why?
|
Australia | 3 | 2021 | 46 | 0.140 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 163 | 0.140 |
Why?
|
Benzoxazines | 2 | 2015 | 119 | 0.140 |
Why?
|
Ecological Momentary Assessment | 1 | 2016 | 1 | 0.140 |
Why?
|
Medical Informatics Applications | 1 | 2016 | 1 | 0.140 |
Why?
|
Health Education | 1 | 2017 | 35 | 0.140 |
Why?
|
Alleles | 2 | 2016 | 134 | 0.140 |
Why?
|
Terminally Ill | 1 | 2017 | 21 | 0.140 |
Why?
|
Immunogenicity, Vaccine | 1 | 2017 | 91 | 0.140 |
Why?
|
United States | 3 | 2021 | 129 | 0.140 |
Why?
|
Sex Workers | 1 | 2018 | 114 | 0.140 |
Why?
|
Gastrostomy | 1 | 2016 | 1 | 0.140 |
Why?
|
Fundoplication | 1 | 2016 | 1 | 0.140 |
Why?
|
DNA Repeat Expansion | 1 | 2016 | 1 | 0.140 |
Why?
|
Attitude to Health | 1 | 2016 | 56 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2016 | 32 | 0.140 |
Why?
|
Biomedical Research | 1 | 2017 | 48 | 0.140 |
Why?
|
Survival Analysis | 3 | 2012 | 149 | 0.140 |
Why?
|
Vascular Stiffness | 1 | 2017 | 41 | 0.130 |
Why?
|
Awareness | 2 | 2015 | 18 | 0.130 |
Why?
|
Multigene Family | 1 | 2016 | 6 | 0.130 |
Why?
|
Forecasting | 1 | 2016 | 20 | 0.130 |
Why?
|
Virus Replication | 1 | 2017 | 87 | 0.130 |
Why?
|
South Australia | 3 | 2021 | 3 | 0.130 |
Why?
|
Disease Progression | 3 | 2019 | 154 | 0.130 |
Why?
|
Mitochondria | 1 | 2016 | 12 | 0.130 |
Why?
|
Genes, Bacterial | 1 | 2016 | 23 | 0.130 |
Why?
|
Recombination, Genetic | 1 | 2016 | 27 | 0.130 |
Why?
|
Drug Industry | 1 | 2015 | 4 | 0.130 |
Why?
|
Mental Disorders | 2 | 2013 | 40 | 0.130 |
Why?
|
Ataxia | 1 | 2015 | 4 | 0.130 |
Why?
|
Bisexuality | 1 | 2015 | 2 | 0.130 |
Why?
|
HIV Protease Inhibitors | 2 | 2014 | 92 | 0.130 |
Why?
|
Chemokine CCL2 | 1 | 2015 | 10 | 0.130 |
Why?
|
Odds Ratio | 5 | 2017 | 132 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2019 | 26 | 0.130 |
Why?
|
Schizophrenic Psychology | 1 | 2015 | 2 | 0.130 |
Why?
|
Schizophrenia | 1 | 2015 | 4 | 0.130 |
Why?
|
Cardiology | 1 | 2015 | 1 | 0.120 |
Why?
|
Psychomotor Performance | 1 | 2015 | 12 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
Synaptophysin | 1 | 2015 | 3 | 0.120 |
Why?
|
Contact Tracing | 1 | 2015 | 47 | 0.120 |
Why?
|
Hematologic Agents | 1 | 2015 | 2 | 0.120 |
Why?
|
Postoperative Hemorrhage | 1 | 2015 | 2 | 0.120 |
Why?
|
Perioperative Care | 1 | 2015 | 8 | 0.120 |
Why?
|
Societies, Medical | 1 | 2015 | 23 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 39 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 190 | 0.120 |
Why?
|
Meningitis, Bacterial | 1 | 2015 | 32 | 0.120 |
Why?
|
Practice Patterns, Physicians' | 1 | 2015 | 42 | 0.120 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2014 | 1 | 0.120 |
Why?
|
Calcitriol | 1 | 2014 | 6 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2014 | 6 | 0.120 |
Why?
|
Zinc Sulfate | 1 | 2014 | 6 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2019 | 507 | 0.120 |
Why?
|
Spatio-Temporal Analysis | 1 | 2014 | 14 | 0.120 |
Why?
|
Tuberculin Test | 1 | 2014 | 49 | 0.110 |
Why?
|
Smoking | 2 | 2015 | 99 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 145 | 0.110 |
Why?
|
Mitochondrial Proteins | 1 | 2013 | 1 | 0.110 |
Why?
|
Encephalitis | 1 | 2013 | 2 | 0.110 |
Why?
|
Research Design | 3 | 2021 | 123 | 0.110 |
Why?
|
Sequence Analysis, DNA | 3 | 2019 | 180 | 0.110 |
Why?
|
Phylogeny | 3 | 2019 | 231 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2012 | 6 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2010 | 237 | 0.110 |
Why?
|
Hospitals, Pediatric | 1 | 2012 | 5 | 0.100 |
Why?
|
Hippocampus | 2 | 2017 | 2 | 0.100 |
Why?
|
Disease Models, Animal | 1 | 2012 | 45 | 0.100 |
Why?
|
Memory Disorders | 1 | 2012 | 1 | 0.100 |
Why?
|
Rural Population | 3 | 2016 | 624 | 0.100 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2012 | 1 | 0.100 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2012 | 1 | 0.100 |
Why?
|
Orthomyxoviridae | 1 | 2012 | 33 | 0.100 |
Why?
|
Unemployment | 1 | 2012 | 10 | 0.100 |
Why?
|
Adenoviridae | 1 | 2012 | 39 | 0.100 |
Why?
|
British Columbia | 3 | 2017 | 4 | 0.100 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2012 | 7 | 0.100 |
Why?
|
Mice | 1 | 2012 | 134 | 0.100 |
Why?
|
Chemoprevention | 1 | 2012 | 33 | 0.100 |
Why?
|
Attention | 1 | 2011 | 5 | 0.100 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2011 | 10 | 0.100 |
Why?
|
Learning | 1 | 2011 | 12 | 0.100 |
Why?
|
Anti-Infective Agents | 2 | 2010 | 56 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 103 | 0.090 |
Why?
|
Latin America | 2 | 2017 | 10 | 0.090 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2008 | 113 | 0.090 |
Why?
|
Liver Diseases | 2 | 2021 | 18 | 0.090 |
Why?
|
Linear Models | 1 | 2010 | 82 | 0.090 |
Why?
|
Hospitals | 2 | 2021 | 102 | 0.090 |
Why?
|
Influenza, Human | 1 | 2014 | 360 | 0.090 |
Why?
|
Malaria | 1 | 2012 | 207 | 0.080 |
Why?
|
Reproducibility of Results | 3 | 2019 | 210 | 0.080 |
Why?
|
Educational Status | 2 | 2013 | 68 | 0.080 |
Why?
|
Hematologic Diseases | 1 | 2009 | 4 | 0.080 |
Why?
|
Sex Factors | 3 | 2018 | 224 | 0.080 |
Why?
|
Family Characteristics | 3 | 2016 | 133 | 0.080 |
Why?
|
Breast Feeding | 1 | 2010 | 119 | 0.080 |
Why?
|
Zidovudine | 1 | 2009 | 59 | 0.080 |
Why?
|
Smartphone | 2 | 2020 | 4 | 0.080 |
Why?
|
Reproduction | 1 | 2009 | 25 | 0.080 |
Why?
|
HIV Antibodies | 1 | 2011 | 243 | 0.080 |
Why?
|
Intestine, Small | 1 | 2008 | 4 | 0.080 |
Why?
|
Intestinal Mucosa | 1 | 2008 | 9 | 0.080 |
Why?
|
Stavudine | 1 | 2009 | 78 | 0.080 |
Why?
|
Liver | 1 | 2008 | 74 | 0.080 |
Why?
|
Women | 2 | 2009 | 12 | 0.080 |
Why?
|
Child, Orphaned | 1 | 2008 | 16 | 0.080 |
Why?
|
Seasons | 2 | 2021 | 149 | 0.070 |
Why?
|
Lipids | 1 | 2008 | 81 | 0.070 |
Why?
|
Diet | 2 | 2021 | 108 | 0.070 |
Why?
|
Safe Sex | 2 | 2018 | 67 | 0.070 |
Why?
|
Pregnancy | 3 | 2021 | 1815 | 0.070 |
Why?
|
Registries | 2 | 2020 | 89 | 0.070 |
Why?
|
DNA, Bacterial | 2 | 2018 | 53 | 0.070 |
Why?
|
Regression Analysis | 2 | 2019 | 131 | 0.070 |
Why?
|
Putamen | 1 | 2006 | 1 | 0.070 |
Why?
|
Microscopy, Confocal | 1 | 2006 | 3 | 0.070 |
Why?
|
Plasma | 2 | 2017 | 39 | 0.070 |
Why?
|
Psychometrics | 1 | 2006 | 20 | 0.070 |
Why?
|
Health Status | 2 | 2019 | 111 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2010 | 467 | 0.070 |
Why?
|
ROC Curve | 2 | 2016 | 47 | 0.060 |
Why?
|
Self Report | 2 | 2019 | 111 | 0.060 |
Why?
|
Cholesterol, HDL | 2 | 2020 | 32 | 0.060 |
Why?
|
Triglycerides | 2 | 2020 | 40 | 0.060 |
Why?
|
Risk | 2 | 2020 | 87 | 0.060 |
Why?
|
Amyloidosis | 1 | 2005 | 3 | 0.060 |
Why?
|
Canada | 2 | 2015 | 11 | 0.060 |
Why?
|
Brain Diseases | 1 | 2005 | 24 | 0.060 |
Why?
|
Caribbean Region | 1 | 2003 | 11 | 0.060 |
Why?
|
Water Supply | 1 | 2003 | 10 | 0.060 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2003 | 17 | 0.060 |
Why?
|
Fluid Therapy | 1 | 2003 | 24 | 0.060 |
Why?
|
United Kingdom | 2 | 2013 | 32 | 0.060 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2003 | 28 | 0.060 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 235 | 0.050 |
Why?
|
Memory, Short-Term | 2 | 2013 | 7 | 0.050 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 5 | 0.050 |
Why?
|
Hepatitis C | 2 | 2014 | 37 | 0.050 |
Why?
|
Alkynes | 2 | 2015 | 113 | 0.050 |
Why?
|
Cyclopropanes | 2 | 2015 | 119 | 0.050 |
Why?
|
Drug Resistance, Viral | 2 | 2014 | 268 | 0.050 |
Why?
|
Fatigue | 1 | 2022 | 20 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 10 | 0.050 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 1 | 0.050 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2021 | 2 | 0.050 |
Why?
|
Prognosis | 2 | 2016 | 197 | 0.050 |
Why?
|
Pain Measurement | 2 | 2012 | 15 | 0.050 |
Why?
|
Respiratory Sounds | 1 | 2021 | 10 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2021 | 34 | 0.050 |
Why?
|
Emtricitabine | 1 | 2021 | 74 | 0.050 |
Why?
|
Multimorbidity | 1 | 2021 | 42 | 0.050 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 2 | 0.050 |
Why?
|
Asia | 1 | 2021 | 70 | 0.050 |
Why?
|
Zambia | 1 | 2021 | 112 | 0.050 |
Why?
|
Ophthalmologists | 1 | 2021 | 1 | 0.050 |
Why?
|
Patients | 1 | 2021 | 3 | 0.050 |
Why?
|
Biomass | 1 | 2021 | 2 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 37 | 0.050 |
Why?
|
Cooking | 1 | 2021 | 7 | 0.050 |
Why?
|
Delphi Technique | 1 | 2021 | 28 | 0.050 |
Why?
|
Consensus | 1 | 2021 | 59 | 0.050 |
Why?
|
New Zealand | 1 | 2020 | 8 | 0.050 |
Why?
|
Waiting Lists | 1 | 2020 | 8 | 0.050 |
Why?
|
Tissue Donors | 1 | 2020 | 17 | 0.050 |
Why?
|
Harm Reduction | 1 | 2020 | 7 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2020 | 2 | 0.040 |
Why?
|
Africa | 1 | 2021 | 360 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2019 | 10 | 0.040 |
Why?
|
Substance Abuse, Intravenous | 2 | 2012 | 11 | 0.040 |
Why?
|
Employment | 2 | 2013 | 27 | 0.040 |
Why?
|
5' Untranslated Regions | 1 | 2019 | 7 | 0.040 |
Why?
|
Cell Count | 1 | 2019 | 10 | 0.040 |
Why?
|
Motor Activity | 2 | 2013 | 46 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 44 | 0.040 |
Why?
|
Health Personnel | 1 | 2021 | 229 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2019 | 38 | 0.040 |
Why?
|
Rubella virus | 1 | 2019 | 8 | 0.040 |
Why?
|
Medical Records | 1 | 2019 | 22 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 271 | 0.040 |
Why?
|
Directive Counseling | 1 | 2019 | 15 | 0.040 |
Why?
|
Health Surveys | 1 | 2019 | 59 | 0.040 |
Why?
|
Chronic Disease | 1 | 2019 | 100 | 0.040 |
Why?
|
Darunavir | 1 | 2018 | 12 | 0.040 |
Why?
|
Mexico | 1 | 2018 | 3 | 0.040 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 68 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2019 | 78 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 153 | 0.040 |
Why?
|
Non-Randomized Controlled Trials as Topic | 1 | 2018 | 1 | 0.040 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 251 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2019 | 328 | 0.040 |
Why?
|
Interrupted Time Series Analysis | 1 | 2018 | 14 | 0.040 |
Why?
|
Ritonavir | 1 | 2018 | 137 | 0.040 |
Why?
|
Geography | 1 | 2018 | 60 | 0.040 |
Why?
|
Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
Antiprotozoal Agents | 1 | 2017 | 6 | 0.040 |
Why?
|
Angiopoietin-2 | 1 | 2017 | 1 | 0.040 |
Why?
|
Receptor, TIE-2 | 1 | 2017 | 1 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2017 | 14 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2018 | 184 | 0.040 |
Why?
|
Immunization, Secondary | 1 | 2017 | 62 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 100 | 0.040 |
Why?
|
Heterosexuality | 1 | 2016 | 30 | 0.030 |
Why?
|
Mosaicism | 1 | 2016 | 1 | 0.030 |
Why?
|
C9orf72 Protein | 1 | 2016 | 2 | 0.030 |
Why?
|
Scotland | 1 | 2016 | 5 | 0.030 |
Why?
|
Artifacts | 1 | 2016 | 3 | 0.030 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2016 | 14 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2017 | 190 | 0.030 |
Why?
|
DNA Primers | 1 | 2016 | 55 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2017 | 149 | 0.030 |
Why?
|
DNA, Mitochondrial | 1 | 2016 | 31 | 0.030 |
Why?
|
Base Sequence | 1 | 2016 | 149 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2016 | 31 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2016 | 60 | 0.030 |
Why?
|
Patient Compliance | 2 | 2007 | 120 | 0.030 |
Why?
|
Knowledge | 1 | 2015 | 2 | 0.030 |
Why?
|
Child, Hospitalized | 1 | 2015 | 25 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2017 | 220 | 0.030 |
Why?
|
Pakistan | 1 | 2015 | 2 | 0.030 |
Why?
|
Genomics | 1 | 2016 | 106 | 0.030 |
Why?
|
Smoking Cessation | 1 | 2015 | 6 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2015 | 31 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2015 | 30 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 380 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 43 | 0.030 |
Why?
|
Cytokines | 1 | 2015 | 107 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2015 | 42 | 0.030 |
Why?
|
Drug Users | 1 | 2014 | 3 | 0.030 |
Why?
|
North America | 1 | 2014 | 11 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 31 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 123 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 18 | 0.030 |
Why?
|
Affect | 1 | 2013 | 4 | 0.030 |
Why?
|
Foot Joints | 1 | 2013 | 1 | 0.030 |
Why?
|
Hand Joints | 1 | 2013 | 1 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2013 | 10 | 0.030 |
Why?
|
Social Stigma | 1 | 2014 | 76 | 0.030 |
Why?
|
Task Performance and Analysis | 1 | 2013 | 5 | 0.030 |
Why?
|
Acute Disease | 1 | 2013 | 105 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2013 | 23 | 0.030 |
Why?
|
Radiography | 1 | 2013 | 80 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 38 | 0.030 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2013 | 10 | 0.030 |
Why?
|
Community Health Services | 1 | 2013 | 58 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2013 | 25 | 0.030 |
Why?
|
Military Personnel | 1 | 2013 | 1 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2014 | 101 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 77 | 0.030 |
Why?
|
Transients and Migrants | 1 | 2013 | 39 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2013 | 111 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2013 | 80 | 0.030 |
Why?
|
Verbal Learning | 1 | 2012 | 3 | 0.030 |
Why?
|
Substance Abuse Detection | 1 | 2012 | 2 | 0.030 |
Why?
|
DNA, Viral | 1 | 2013 | 165 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2012 | 26 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2011 | 26 | 0.020 |
Why?
|
Opioid-Related Disorders | 1 | 2011 | 1 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2011 | 20 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 76 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2011 | 37 | 0.020 |
Why?
|
Mycobacterium | 1 | 2011 | 16 | 0.020 |
Why?
|
Critical Illness | 1 | 2010 | 42 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 247 | 0.020 |
Why?
|
Hematologic Tests | 1 | 2009 | 11 | 0.020 |
Why?
|
Transaminases | 1 | 2008 | 5 | 0.020 |
Why?
|
Hyperplasia | 1 | 2008 | 1 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2008 | 12 | 0.020 |
Why?
|
Home Care Services | 1 | 2008 | 15 | 0.020 |
Why?
|
Mothers | 1 | 2010 | 190 | 0.020 |
Why?
|
Cholesterol | 1 | 2008 | 38 | 0.020 |
Why?
|
Survival Rate | 1 | 2008 | 96 | 0.020 |
Why?
|
Child Mortality | 1 | 2008 | 93 | 0.020 |
Why?
|
Nevirapine | 1 | 2008 | 146 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2008 | 137 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2005 | 2 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 235 | 0.010 |
Why?
|
Neurologic Examination | 1 | 2004 | 5 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2004 | 45 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 64 | 0.010 |
Why?
|